Canagliflozin does not increase risk of below- knee amputation in people with type 2 diabetes

893 Views

eMediNexus 01 July 2018

Canagliflozin does not increase the risk of amputation for the general type 2 diabetes population or in patients with established cardiovascular disease, but does reduce a patient’s risk of hospitalization for heart failure, according to a study presented June 24, 2018 at the 78th Scientific Session of the ADA in Orlando, Florida.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.